Axsome Therapeutics Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migraine
Over 21,000 migraine attacks treated with AXS-07 Achieved migraine pain relief in approximately 70% of patients, and pain freedom in approximately 40% of patients, at...

